Pergamon

0163-7258(95)02017-9

Pharmac. Ther. Vol. 68, No. 3, pp. iii–xii, 1995
Copyright © 1995 Elsevier Science Inc.
Printed in Great Britain. All rights reserved
0163-7258/95 $29.00

CONTENTS, 1995

Volume 65 No. 1 — Contents — 1995

H. W. Müller, U. Junghans and J. Kappler	1	Astroglial neurotrophic and neurite-promoting factors
T. Haaf	19	The effects of 5-azacytidine and 5-azadeoxycytidine on chromosome structure and function: Implications for methylation-associated cellular processes
G. M. Dusheiko	47	Treatment and prevention of chronic viral hepatitis
W. J. Pearce	75	Mechanisms of hypoxic cerebral vasodilatation
R. A. Rush, R. Mayo and C. Zettler	93	The regulation of nerve growth factor synthesis and delivery to peripheral neurons
M. J. Shield	125	Novel applications of misoprostol

Volume 65 No. 2 — Contents — 1995

M. David	149	Transcription factors in interferon signaling
M. McLean and M. F. Dutton	163	Cellular interactions and metabolism of aflatoxin: an update
J. R. Cockcroft, K. P. J. O'Kane and D. J. Webb	193	Tissue angiotensin generation and regulation of vascular tone
L. Poston, A. L. McCarthy and J. M. Ritter	215	Control of vascular resistance in the maternal and feto-placental arterial beds
D. Healy and J. M. Waterhouse	241	The circadian system and the therapeutics of the affective disorders
P. F. Rockley and S. K. Tyring	265	Interferons alpha, beta and gamma therapy of anogenital human papillomavirus infections

Volume 65 No. 3 — Contents — 1995

B. D. Curti and J. W. Smith, II	291	Interleukin-1 in the treatment of cancer
R. E. Powers, G P. Lawton and I. M. Modlin	303	Genotoxicity, carcinogenicity and acid-suppressing medications
G. Griebel	319	5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: More than 30 years of research

J. G. Wettstein, B. Earley and J. L. Junien **397** Central nervous system pharmacology of neuropeptide Y

S. Landolfo, G. Gribaudo, A. Angeretti and M. Gariglio **415** Mechanisms of viral inhibition by interferons

Volume 66 No. 1 Contents 1995

R. Poupon and R. E. Poupon **1** Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children

H. H. G. Berendsen **17** Interactions between 5-hydroxytryptamine receptor subtypes: Is a disturbed receptor balance contributing to the symptomatology of depression in humans?

H. Brachwitz and C. Vollgraf **39** Analogs of alkyllysophospholipids: Chemistry, effects on the molecular level and their consequences for normal and malignant cells

M. Mazière **83** Cholinergic neurotransmission studied *in vivo* using positron emission tomography or single photon emission computerized tomography

S. L. Handley **103** 5-Hydroxytryptamine pathways in anxiety and its treatment

R. M. K. W. Lee **149** Morphology of cerebral arteries

K. A. Whartenby, G. N. Abraham, P. A. Calabresi, C. N. Abboud, P. Calabresi, A. Marrogi and S. M. Freeman **175** Gene-modified cells for the treatment of cancer

Volume 66 No. 2 Contents 1995

T. Ganz and R. I. Lehrer **191** Defensins

E. F. Gudgin Dickson, A. Pollak and E. P. Diamandis **207** Ultrasensitive bioanalytical assays using time-resolved fluorescence detection

A. M. Gulick and W. E. Fahl **237** Mammalian glutathione S-transferase: regulation of an enzyme system to achieve chemotherapeutic efficacy

D. A. Cook **259** Mechanisms of cerebral vasospasm in subarachnoid haemorrhage

G. Labrecque, J.-P. Bureau and A. E. Reinberg **285** Biological rhythms in the inflammatory response and in the effects of non-steroidal anti-inflammatory drugs

A.-M. Craig and M. Malek **301** Market structure and conduct in the pharmaceutical industry

P. R. Saxena **339** Serotonin receptors: subtypes, functional responses and therapeutic relevance

C. Dodds **369** Anaesthetic drugs in the elderly

M. Pinzani **387** Novel insights into the biology and physiology of the Ito cell

Volume 66 No. 3 **Contents** **1995**

R. Leurs, M. J. Smit and H. Timmerman **413** Molecular pharmacological aspects of histamine receptors

K. M. McGowan, S. D. Long and P. H. Pekala **465** Glucose transporter gene expression: Regulation of transcription and mRNA stability

M. A. Horisberger and S. Di Marco **507** Interferon-alpha hybrids

R. H. Scott, K. G. Sutton, A. Griffin, S. R. Stapleton and K. P. M. Currie **535** Aspects of calcium-activated chloride currents: A neuronal perspective

Volume 67 No. 1 **Contents** **1995**

C. Focan **1** Circadian rhythms and cancer chemotherapy

C. Fleck and H. Bräunlich **53** Renal handling of drugs and amino acids after impairment of kidney or liver function—Influences of maturity and protective treatment

H. Vanden Bossche, L. Koymans, and H. Moereels **79** P450 inhibitors of use in medical treatment: Focus on mechanisms of action

B. Fromenty and D. Pessayre **101** Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity

Volume 67 No. 2 **Contents** **1995**

E. S. J. Arnér and S. Eriksson **155** Mammalian deoxyribonucleoside kinases

D. I. B. Kerr and J. Ong **187** $GABA_B$ receptors

S. H. Safe **247** Modulation of gene expression and endocrine response pathways by 2,3,7,8-tetrachlorodibenzo-*p*-dioxin and related compounds

M. Schwarz, D. Glick, Y. Loewenstein, and H. Soreq **283** Engineering of human cholinesterases explains and predicts diverse consequences of administration of various drugs and poisons

Volume 67 No. 3 **Contents** **1995**

H. R. Matthews **323** Protein kinases and phosphatases that act on histidine, lysine, or arginine residues in eukaryotic proteins: A possible regulator of the mitogen-activated protein kinase cascade

M. C. Walker and P. N. Patsalos **351** Clinical pharmacokinetics of new antiepileptic drugs

F. Dauphin and E. T. MacKenzie **385** Cholinergic and vasoactive intestinal polypeptidergic innervation of the cerebral arteries

R. E. Appleton **419** Treatment of childhood epilepsy

C. R. Sirtori **433** New targets for lipid lowering and atherosclerosis prevention

Volume 68 No. 1 **Contents** **1995**

E. Alborch, J. B. Salom, and G. Torregrosa **1** Calcium channels in cerebral arteries

D. Cioli, L. Pica-Mattoccia, and S. Archer **35** Antischistosomal drugs: Past, present . . . and future?

L. F. Garrity and G. W. Ordal **87** Chemotaxis in *Bacillus subtilis*: How bacteria monitor environmental signals

H. Ono and H. Fukuda **105** Pharmacology of descending noradrenergic systems in relation to motor function

A. L. Harvey **113** The pharmacology of galanthamine and its analogues

G. Labrecque and M.-C. Vanier **129** Biological rhythms in pain and in the effects of opioid analgesics

G. Powis, M. Briehl, and J. Oblong **149** Redox signalling and the control of cell growth and death

Volume 68 No. 2 **Contents** **1995**

N. French **175** α_2-Adrenoceptors and I_2 sites in the mammalian central nervous system

G. E. Mawer and B. J. Pleuvry **209** Interactions involving new antiepileptic drugs

V. S. N. M. R. Karamsetty, K. A. Kane, and R. M. Wadsworth **233** The effects of chronic hypoxia on the pharmacological responsiveness of the pulmonary artery

H. Kijima, H. Ishida, T. Ohkawa, M. Kashani-Sabet, and K. J. Scanlon **247** Therapeutic applications of ribozymes

L. P. Rivory and J. Robert **269** Molecular, cellular, and clinical aspects of the pharmacology of 20(*S*)camptothecin and its derivatives

S. C. Stanford **297** Central noradrenergic neurones and stress

Volume 68 No. 3 **Contents** **1995**

M. Satoh and M. Minami **343** Molecular pharmacology of the opioid receptors

M. Y. Aglan and B. J. Pollard **365** Molecular mechanisms of neuromuscular blocking agents: Is the increased understanding of importance to the practising anaesthetist?

B. K. Park, M. Pirmohamed, and N. R. Kitteringham **385** The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity

B. á Rogvi-Hansen and L. Gram **425** Adverse effects of established and new antiepileptic drugs: An attempted comparison

M. Sokolovsky **435** Endothelin receptor subtypes and their role in transmembrane signaling mechanisms

J. Lincoln **473** Innervation of cerebral arteries by nerves containing 5-hydroxytryptamine and noradrenaline